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Abstract To date, only two splice-site mutations within
the TPM2 gene have been shown to be causative for
congenital myopathies. While the majority of TPM2
gene mutations are causative for nemaline myopathy,
cap disease or distal arthrogryposis, some mutations in
this gene have been found to be associated with non-
specific congenital myopathy. We report on a patient
with such an unspecified congenital myopathy associat-
ed with distinctive facial dysmorphic features and distal
arthrogryposis. Using the whole exome sequencing
(WES) approach we were able to identify a novel het-
erozygous splice-site mutation within the TPM2 gene,
showing the utility of WES in molecular diagnostics
of congenital myopathies without recognizable morpho-
logical hallmarks.
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Introduction
The tropomyosins (TPMs), encoded by four genes (α, β,
γ, and δ), are involved in a wide spectrum of cellular
processes (Gunning et al. 2005). In the striated and
smooth muscle, TPMs are key regulators of calcium–de-
pendent muscle contraction. TPM binds to actin fila-
ments, which become permissive for myosin II interac-
tions (Gunning et al. 2005). TPM2 is expressed mainly
in slow type-1 muscle fibers (Tajsharghi et al. 2012).
Mutations in the β-tropomyosin gene (TPM2) have been
shown to be associated with a spectrum of phenotypes ranging
from a pure distal arthrogryposis (DA) to cap disease and
nemaline myopathy (Tajsharghi et al. 2012).
Though almost all TPM2 gene mutations are inherited
in an autosomal dominant manner, one homozygous non-
sense TPM2 mutation was found in a patient with a very
severe nemaline myopathy (Monnier et al. 2009). Two
TPM2 mutations, i.e., c.349G>A, p.Glu117Lys and,
c.364G>A; p.Glu122Lys, were identified in an unspeci-
fied congenital myopathy, diagnosed in the patients with-
out specific structural alterations in the muscle biopsy
specimen (Brandis et al. 2008; Donner et al. 2002).
Some of the TPM2 gene mutations were reported to be
associated with congenital fiber type disproportion
(CFTD). Among 27 TPM2 mutations reported to date in
congenital myopathies, only two, i.e., c.240+2T>C and
c.240+5G>A, are splice-site mutations (Marttila et al.
2014). Interestingly, a recurrent TPM2 mutation,
c.20_22delAGA, p.Lys7del, is responsible for two distinct
clinical entities, i.e., core-rod myopathy and distal
arthrogryposis type 7 (Davidson et al. 2013). In this study
we report on a patient manifesting a combined phenotype
of facial dysmorphism, unspecified congenital myopathy,
and distal arthrogryposis.
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Frozen sections of a quadriceps femoris muscle sample were
stained with hematoxylin and eosin, modified Gomori
trichrome, oil red O, and picrosirius red. Histochemical reac-
tions included: succinate dehydrogenase; NADH dehydroge-
nase; cytochrome c oxidase, myosin ATP-ase at pH 4.3; 4.6;
and 9.4. An immunohistochemical controlled panel for dys-
trophin, beta sarcoglycan, spectrin, and merosin was also
performed.
Molecular analysis
The exome sequencing in the proband was performed in line
with the protocol from Illumina’s TruSeq Exome Enrichment
Guide. Exome capture was performed on the genomic DNA
with a SureSelect Human All Exon 50 Mb Kit (Agilent
Technologies) and theHiSeq 2000 instrument (Illumina).
Exome sequencing was performed by the firm Intelliseq sp.
z o.o., based in Cracow. The sequence reads were analyzed
using an Illumina pipeline, with reads processed by Picard
and aligned to a human reference sequence (GRCh37) using
Bowtie 2 (Langmead and Salzberg 2012). SAMtoolswere used
to obtain BAM files for analyzing samples (Li and Durbin
2009) and removing duplicated reads. Variant calling was then
performed using a Genome Analysis Toolkit (GATK)
(McKenna et al. 2010). NGS variants analysis were done on
the Galaxy platform (Blankenberg et al. 2010; Giardine et al.
2005; Goecks et al. 2010). The data were filtered by genotype:
the proband as heterozygous or homozygous alternative and
parents as homozygous reference or heterozygous, with 12
other control probes being used as homozygous reference.
Data were then annotated with dbSNP and SnpEff, and com-
mon sequence variants were filtered out. The SIFT tool
(Kumar et al. 2009; Ng and Henikoff 2001, 2002, 2003) and
SnpSift (Cingolani et al. 2012) were used for conservation
analysis and effect prediction in relation to SNPs. Finally,
filtering for rare and probably protein deleterious variants
was carried out. The presence of WES detected variants was
confirmed by Sanger sequencing. To estimate the influence of
the mutation on the RNA transcript, total RNA was isolated
from leukocytes and after reverse transcription the fragment of
TPM2 cDNA covering exons 2, 3, and 4 was amplified using
designed primers (on request), and sequenced directly. The
length of the cDNA fragment was measured on GeneScan.
The CGH analysis was performed using the Agilent Human
GenomeG3 Sure Print 8 × 60Microarray (Agilent Technologies,
USA) with resolution over 100 kb.
DNA samples obtained from 100 healthy controls (200
chromosomes) were screened for mutation c.374+2T>C in
the TPM2 gene, using the RFLP-PCR approach with Aci I
restriction enzyme.
Results
Clinical features of the proband
The female proband was born to young, unrelated parents (a
mother and father aged 29 and 32 years, respectively), after
two miscarried pregnancies.
In the mother, the homozygous c.1298A>C, p.Glu433Ala
mutation in the MTHFR (1p36.3) gene was identified and
antiphospholipid syndrome diagnosed in the regional hospital.
A non-invasive 1st-trimester prenatal screening was carried
out since nuchal translucency and polyhydramnios were re-
vealed by ultrasound scanning. The PAPP-A test indicated an
increased risk of Down syndrome. Prenatal cytogenetic anal-
ysis revealed a normal female karyotype (46,XX). Smith–
Lemli–Opitz syndrome was excluded by analysis of levels
of amniotic fluid 7 and 8-dehydrocholesterol (7/8-DHC).
Magnetic resonance imaging (MRI) performed at 24 weeks
of gestation suggested a coccygeal bone defect, cloacal anom-
aly, and bilateral clubfoot.
Cesarean section was performed at 35 weeks of gesta-
tion, due to fetal condition complicated by intrauterine
growth retardation and polyhydramnios. Her birth weight
was 1900 g (-1.1 SD; 13th centile) and the Apgar score
was 4 at 1st minute. The baby was admitted to the neo-
natal intensive care unit (NICU) in the regional hospital
for mechanical ventilation, because the clinical course
was seriously complicated by pulmonary hypertension
and generalized hypotonia. The baby did not demonstrate
either a suck reflex or a swallowing reflex. On admission,
dysmorphic facial features were recorded such as
hyper te lo r i sm and prominen t eyes , as we l l as
hypertrichosis of the sacroiliac region, contractures of
wrists, knees, fingersand toes, and bilateral clubfoot.
Transcranial ultrasonography showed intraventricular
hemorrhage (IVH) of I and II degree, and asymmetry of
the ventricles. MRI indicated corpus callosum hypoplasia
and shallow orbits. An X-ray of the entire body
(babygram) did not show symptoms of generalized genet-
ic bone disease, while an X-ray of the thorax revealed a
raised diaphragm. The methylation test for Prader-Willi
syndrome (PWS) showed normal pattern of methylation
in chromosome 15q11-13 region. Deletions of exons 7
and 8 of the SMN1 gene were excluded.
On the 93rd day of life she was admitted to the
Intensive Care Unit at the Children’s Memorial Health
Institute (CMHI) in Warsaw, where a tracheotomy was
performed due to a persistent generalized hypotonia and
necessity of permanent mechanic ventilation. A muscle
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biopsy performed at the age of 7 months revealed con-
genital fiber type disproportion (CFTD). Auditory
evoked potentials (AEP) showed bilateral sensorineural
hypoacusis. The patient was nourished using an NG-
tube. She was discharged home after a four-month hos-
pitalization in a stable state, and home mechanical ven-
tilation (HMV) was recommended.
At 10 months of life the baby manifesting poor weight gain
(5450 g; −4.5 SDS) was readmitted to the CMHI and a
gastrostomy tube (G-tube) was inserted. At the age of
11 months her growth was still severely retarded: length
73 cm (−2.67 SDS), head circumference 44.5 cm
(−2.24 SDS), weight 6.4 kg (−3.16 SDS), and BMI 12.1
(−3.13 SDS), although she put on weight substantially.
At the age of 13 months, despite intensive physiotherapy,
contractures in the small joints of the hands and feet (with
overlapping fingers and toes), as well as in the knee and at
the hip joints were present. There was reduced flexion of the
wrist and elbow joint. Both patellar reflexes were present. The
child presented with pectus excavatum and generalized hypo-
tonia. The patient had a hearing aid due to the sensorineural
hypoacusis in both ears. Mechanical ventilation was needed
almost constantly (Fig. 1). The patient died suddenly aged
2 years and 8 months.
Quadriceps femoris muscle biopsy
Skeletal muscle revealed considerable bimodal variability of
muscle-fiber diameters (4–25 μm) with selective smallness of
type-1 fibers. No other essential abnormalities were found.
The result was concluded to be a congenital muscle fiber type
disproportion (Fig. 2).
Molecular analysis
No pathogenic mutations in LMNA, IGHMBP2, EGR2,
MTMR2, and SBF2 genes were found using the Sanger se-
quencing method.
A whole-exome sequencing analysis revealed a novel
splice-site c.374+2T>C mutation within the TPM2 gene in
the proband (confirmed by a Sanger method). The mutation
was not present in 100 healthy controls (200 chromosomes)
from the Polish population.
Gene Scan analysis of the TPM2 cDNA fragment in the
proband revealed two peaks, which correspondwith two prod-
ucts, i.e., a longer RNA transcript of about 463 bp and a
normal–length, wild-type RNA transcript of about 368 bp.
In the proband’s parents only one peak (368 bp) correspond-
ing with the normal wild-type RNA transcript was detected.
The sequencing of the cDNA in the proband showed that the
RNA transcript in addition contains the whole sequence of the
3rd intron of the TPM2 gene (of 95 bp) (Fig. 3).
Bioinformatics analysis indicated that a longer RNA tran-
script results in frameshift at a codon 125, and a premature stop
codon 34 aa downwards. Thus, by in silico translation, the mu-
tation results in a truncated TPM2 protein (p.Gly125TrpfsX34).
A whole-exome sequencing analysis (with sequence vari-
ants filtered as described in Methods) carried out in the pro-
band revealed rare sequence variants in more than 200 genes,
including these involved in the pathogenesis of neuromuscu-
lar disorders.
Discussion
In this study we document a patient with a severe form of
unspecified congenital myopathy, with arthrogryposis and fa-
cial dysmorphic features, in whom a new splice-site mutation
Fig. 1 The proband aged 13 months, manifesting dysmorphic
craniofacial features: elongated face with bitemporal narrow forehead,
low frontal hairline, widely spaced and prominent eyes, short nose with
depressed nasal bridge, underdeveloped nasolabial fold, and open mouth
Fig. 2 Skeletal muscle biopsy, myosin ATP-ase at pH 4.3. Original
magnification 600×. Congenital fiber type disproportion pattern
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within the TPM2 gene was found. Functional studies of the
TPM2 c.374+2T>C mutation confirmed the pathogenic effect
of this mutation.
The molecular diagnostics process in the proband proved
extremely difficult, due to a lack of any specific ultrastructural
features for the congenital myopathy. Two mutations within
the TPM2 gene have been found previously in patients man-
ifesting CFTD upon muscle biopsy. The authors suggested
that, especially in the case of muscle biopsies taken at very
young ages (5, 6 or 8 months), no specific abnormalities may
be found (Marttila et al. 2014). Moreover, Lehtokari reported
on a patient presenting cap structures at age 33 years, in the
second muscle biopsy (Lehtokari et al. 2007). Given that ac-
cumulation of mutated proteins occurs over time, it is possible
that, in very young children in particular, no specific alter-
ations in a muscle specimen may yet be present. Our observa-
tions do fit accurately with this hypothesis. Interestingly,
therefore, with a classical approach to genetic analysis direct-
ed by the ultrastructure in the congenital myopathy, the mo-
lecular diagnostics process could be misdirected. In such
cases, whole-exome sequencing represents a very useful ap-
proach not influenced by the histopathological findings.
Only two splice-site mutations within the TPM2 gene have
been reported to date in patients with congenital myopathy.
The pathogenic character of the c.374+2T>C mutation in the
TPM2 gene has been documented by us. First, the c.374+
2T>C mutation is associated with the phenotype of CFTD as
previously reported in patients with mutations in the TPM2
gene (Marttila et al. 2014). Second, the c.374+2T>Cmutation
is located in a highly conservative position which is critical to
an appropriate splicing process.
The c.374+2T>C mutation was not detected in the control
group. Moreover, the c.374+2T>C mutation was selected in the
algorithms of the whole-exome sequencing as the strongest de
novo sequence variant among thousands of variants detected.
Using the WES approach we have also checked other genes
associated with neuromuscular disorders, in which nomutations
have been detected. Since the procedure used by us was not a
single-gene analysis, we have evidence for the pathogenic
nature of the c.374+2T>C mutation. Moreover, in the analysis
of the cDNA, we have shown that the c.374+2T>C mutation
results in an aberrantly spliced transcript containing the 3rd in-
tron of the TPM2 gene. Typically for other TPM2mutations, the
c.374+2T>C sequence variant occurs in a de novo configuration
and is inherited as an autosomal dominant fashion.
A combined phenotype of the congenital myopathy, distal
arthrogryposis and facial dysmorphic features, we observed in
the patient may be associated with a pleiotropic effect of the
c.374+2T>C mutation.
On the other hand, we cannot exclude that the additional
point mutations found using our WES approach have any
modifying effect.
To conclude, our study documents the phenotype associated
with a new heterozygous c.374+2T>C mutation within the
TPM2genesegregatingwithanunspecifiedcongenitalmyopathy
accompanied by facial dysmorphism and arthrogryposis. This
study points to the utility of the WES approach, especially in
patientsnotmanifestingwithanyspecificmorphologicalfeatures,
i.e., patients in which the muscle biopsy is taken very early. The
pathogenic effect of the c.374+2T>C mutation has been
established in relation to many lines of evidence which were
available.WehaveshownthatWESapproachshouldbeespecial-
ly recommended in the patientsmanifestingwith an overt pheno-
type of congenital myopathy without any specific features in the
electronmicroscope analysis.
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